After more than three decades at Neurocrine, CEO Kevin Gorman will retire later this year, handing the reins of the $13 billion neuroscience drugmaker over …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The orphan drug designation programme is an FDA initiative to support the development of new treatments for rare diseases. Credit: Kateryna Kon via Shutterstock. The
Dive Brief: Henry Schein has taken “certain systems offline” after a cybersecurity incident at “a portion of its manufacturing and distribution businesses.” The company, which
Dupilumab (Dupixent), an interleukin (IL)-4/IL-13-blocking antibody, significantly reduced nitric oxide levels compared to placebo and reduced mucus plug scores by as early as 4 weeks,